Drug Patents owned by Glaxo Grp Ltd
1. List of Advair Hfa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7832351 | GLAXO GRP LTD | Actuation indicator for a dispensing device |
Jun, 2023
(10 days from now) | |
|
US7832351 (Pediatric) | GLAXO GRP LTD | Actuation indicator for a dispensing device |
Dec, 2023
(6 months from now) | |
| US7500444 | GLAXO GRP LTD | Actuation indicator for a dispensing device |
Feb, 2026
(2 years from now) | |
|
US7500444 (Pediatric) | GLAXO GRP LTD | Actuation indicator for a dispensing device |
Aug, 2026
(3 years from now) | |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 08 June, 2006
Treatment: NA
Dosage: AEROSOL, METERED;INHALATION
2. List of Breo Ellipta drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE44874 | GLAXO GRP LTD | Phenethanolamine derivatives for treatment of respiratory diseases |
Mar, 2023
(2 months ago) | |
| US7439393 | GLAXO GRP LTD | Phenethanolamine derivatives for treatment of respiratory diseases |
May, 2025
(1 year, 11 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7776895 | GLAXO GRP LTD | Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases |
Sep, 2022
(8 months ago) | |
| US8511304 | GLAXO GRP LTD | Medicament dispenser |
Jun, 2027
(4 years from now) | |
| US9333310 | GLAXO GRP LTD | Medicament dispenser |
Oct, 2027
(4 years from now) | |
| US8113199 | GLAXO GRP LTD | Counter for use with a medicament dispenser |
Oct, 2027
(4 years from now) | |
| US8161968 | GLAXO GRP LTD | Medicament dispenser |
Feb, 2028
(4 years from now) | |
| US11116721 | GLAXO GRP LTD | Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol |
Feb, 2029
(5 years from now) | |
| US8534281 | GLAXO GRP LTD | Manifold for use in medicament dispenser |
Mar, 2030
(6 years from now) | |
| US8746242 | GLAXO GRP LTD | Medicament dispenser |
Oct, 2030
(7 years from now) | |
Drugs and Companies using FLUTICASONE FUROATE; VILANTEROL TRIFENATATE ingredient
Market Authorisation Date: 10 May, 2013
Treatment: Indicated for the once-daily inhaled treatment for asthma in adults aged 18 years and older; Long-term, once daily maintenance treatment of airflow obstruction in pts with copd, including chronic bron...
Dosage: POWDER;INHALATION
BREO ELLIPTA family patents
27
United States
24
European Union
17
United Kingdom
13
Japan
11
Spain
10
Brazil
10
China
10
Denmark
10
Australia
9
Poland
9
Portugal
8
Canada
8
South Africa
8
Cyprus
7
Korea, Republic of
7
Hong Kong
7
Mexico
6
Hungary
6
Norway
5
New Zealand
5
Israel
3
Slovenia
3
Argentina
2
Taiwan
2
Germany
2
Malaysia
2
Colombia
2
Austria
2
Russia
2
Singapore
1
Luxembourg
1
Lithuania
1
Belgium
1
Croatia
3. List of Flovent Hfa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7832351 | GLAXO GRP LTD | Actuation indicator for a dispensing device |
Jun, 2023
(10 days from now) | |
|
US7832351 (Pediatric) | GLAXO GRP LTD | Actuation indicator for a dispensing device |
Dec, 2023
(6 months from now) | |
| US7500444 | GLAXO GRP LTD | Actuation indicator for a dispensing device |
Feb, 2026
(2 years from now) | |
|
US7500444 (Pediatric) | GLAXO GRP LTD | Actuation indicator for a dispensing device |
Aug, 2026
(3 years from now) | |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 14 May, 2004
Treatment: NA
Dosage: AEROSOL, METERED;INHALATION
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic